Thynk Capital

IMX Health operates a futures and derivatives exchange dedicated to the healthcare industry. The platform establishes a transparent two-sided market for pricing healthcare assets and provides hedging tools for payers, providers, and other market participants. By enabling stakeholders to hedge risk and trade healthcare-related instruments, the company aims to improve pricing transparency, reduce volatility, and promote competition. This competition is intended to translate into more efficient service pricing and, over time, lower costs for patients and payers.

IVIVA Medical, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative therapies for end-stage renal disease (ESRD). Founded in 2013, the company aims to address the critical shortage of donor organs by creating autologous tissue constructs that provide alternative treatments for patients suffering from this condition, which affects over 500,000 individuals in the United States. IVIVA Medical leverages advanced technologies in tissue engineering, 3D additive manufacturing, and stem cell biology to create bioartificial platforms and systems. These platforms not only facilitate therapeutic applications but also serve as essential building blocks for the next generation of engineered, functionalized tissues, positioning IVIVA Medical at the forefront of regenerative medicine and enhancing the capacity of medical professionals to manage end-stage kidney disease.

Founded in 2017, Viscient Biosciences is a biotechnology company based in San Diego, California. It specializes in drug discovery across various therapeutic areas, focusing on non-alcoholic steatohepatitis (NASH). The company combines human 3D tissue technology with multi-omics analysis to revolutionize drug development.

Repair Biotechnologies, Inc. is a biotechnology company founded in 2018 and based in Syracuse, New York. The company focuses on developing innovative therapies aimed at reversing the progression of age-related conditions such as immunosenescence and atherosclerosis. Utilizing a cholesterol-degrading platform, Repair Biotechnologies creates treatments that address conditions driven by excess or modified cholesterol, including atherosclerosis and familial hypercholesterolemia. Their approach centers on gene therapy and recombinant protein strategies, designed to be safe and well-tolerated, allowing patients to target the underlying causes of diseases associated with cholesterol accumulation.

X-Vax Technology is a biotechnology company established in 2015 and headquartered in Jupiter, Florida. Its primary focus is the preclinical and clinical development of vaccines targeting mucosal infections caused by pathogens, including herpes, influenza, tuberculosis, and HIV, which affect millions globally. X-Vax is known for its development of a herpes vaccine candidate based on a genetically altered HSV-2 virus, specifically designed to elicit a robust immune response by inducing antibodies that lead to the killing of infected cells. This innovative approach utilizes Fc receptor activating antibodies that facilitate antibody-dependent cell-mediated killing, aiming to provide effective protection against herpes types 1 and 2. Through its pioneering research, X-Vax intends to advance the field of vaccines and enhance immune responses against significant viral infections.

Repair Biotechnologies, Inc. is a biotechnology company founded in 2018 and based in Syracuse, New York. The company focuses on developing innovative therapies aimed at reversing the progression of age-related conditions such as immunosenescence and atherosclerosis. Utilizing a cholesterol-degrading platform, Repair Biotechnologies creates treatments that address conditions driven by excess or modified cholesterol, including atherosclerosis and familial hypercholesterolemia. Their approach centers on gene therapy and recombinant protein strategies, designed to be safe and well-tolerated, allowing patients to target the underlying causes of diseases associated with cholesterol accumulation.

Elicio Therapeutics, a biotechnology company based in Cambridge, Massachusetts, specializes in developing innovative immunotherapies for treating aggressive cancers. Its proprietary Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, amplifying the body's immune response against cancer.

KitoTech Medical, Inc. is a medical device company based in Seattle, Washington, specializing in the development and commercialization of innovative products for wound closure and care. Established in 2011, the company has introduced microMend, a proprietary wound closure device featuring tiny Microstaples on an adhesive backing, designed for ease of application similar to a bandage. microMend is painless to use and offers the holding strength of traditional sutures, making it suitable for closing surgical incisions and lacerations. Clinical studies indicate that microMend outperforms sutures in terms of clinical outcomes, including cosmetic results, and allows for quicker application by various medical personnel, resulting in considerable cost savings. The product is marketed across a range of surgical specialties, as well as in dermatology and emergency medicine, with additional opportunities in military applications. KitoTech Medical targets a potential market exceeding $600 million in the US and $2 billion worldwide.

Marina Biotech focuses on providing effective and patient-centric treatments for hypertension, including resistant hypertension. Their commercial product, Prestalia®, approved by the US FDA, is distributed through the DyrctAxess platform. Additionally, the company is developing non-addictive pain therapeutics like IT-102 and IT-103, designed to address the side effects of edema and potentially replace opioids to combat the opioid epidemic. Their goal is to create a universal platform for the distribution of fixed-dose combination hypertensive drugs, aiming to revolutionize the treatment of hypertension and improve patient outcomes.

Founded in 2017, Elevian is a biotechnology company dedicated to developing regenerative medicines. It focuses on restoring the body's natural repair mechanisms to prevent and treat age-related diseases such as stroke recovery, Alzheimer's disease, coronary artery disease, and Type 2 diabetes.

Theragene Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for debilitating diseases, particularly in oncology and cardiology. Operating in both the United States and Asia, the company leverages unique product development models that capitalize on the strengths of each region, ensuring the delivery of safe and effective treatments. Theragene specializes in immunotherapy and gene therapy technologies, enhancing the body's capacity to recognize and combat tumor cells. Its gene therapy platform employs adeno-associated virus technology to provide safe alternatives for cardiovascular disease treatments. Committed to advancing medicine, Theragene aims to transform promising scientific advancements into viable therapies, progressing from preclinical stages to finished products.

Klotho Therapeutics is a biotechnology company developing engineered human Klotho proteins to treat aging-related diseases and slow kidney conditions. The company aims to delay aging processes and address conditions such as kidney failure, chronic kidney disease, Alzheimer's disease, cancer, diabetes, osteoporosis, and hypertension by using modified Klotho proteins derived from the naturally occurring protein. Established in 2016 and based in San Diego, it pursues patent-pending designs and seeks to improve longevity by reducing the burden of aging-associated illnesses through novel protein therapeutics.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Founded in 2013, Curtana Pharmaceuticals is dedicated to developing targeted therapies for aggressive brain cancers. Headquartered in Austin, Texas, the company's lead drug candidate, CT-179, aims to prolong survival in relevant animal models. Curtana's team comprises experienced pharmaceutical industry professionals, and its research is based on the pioneering work of Dr. Santosh Kesari.

WinSanTor Inc. is a clinical-stage biotechnology company based in San Diego, California, dedicated to the discovery and development of innovative treatments for various forms of peripheral neuropathy, including diabetic, chemo-induced, and HIV-induced neuropathies. Founded in 2011, the company focuses on identifying and developing compounds that promote neuroprotection and neuroregeneration of damaged neurons. Notably, WinSanTor has developed a compound known as WST57, which supports its mission to provide therapeutic solutions that can prevent and reverse nerve damage associated with these conditions.

Lubris BioPharma, LLC is a biopharmaceutical company based in Framingham, Massachusetts, founded in 2009. The company specializes in developing and commercializing recombinant human lubricin, a protein that plays a critical role in protecting tissues from friction-related damage. Lubricin is utilized in the treatment of various conditions, including dry eye, osteoarthritis, surgical adhesions, xerostomia, and pericarditis, among others. By providing a therapeutic option that addresses age and inflammation-related issues, Lubris BioPharma aims to enhance patient care and improve treatment outcomes in related medical fields.